Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
about
Repurposing the anti-malarial drug, quinacrine: new anti-colitis propertiesNew concepts in antimalarial use and mode of action in dermatology.Treatment of cutaneous lupus.Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment.Therapeutic options for rheumatoid arthritis.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats.Chloroquine Suppresses the Development of Hypertension in Spontaneously Hypertensive Rats.A girl with cutaneous lesions, polyarthritis, and antinuclear antibodies positivity.Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment.Erythema, atrophy, and scarring on the face and arm of a young girl.Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus.Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients.Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naïve systemic lupus erythematosus.Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation.Vitamin D levels in 87 Asian patients with cutaneous lupus erythematosus: a case-control study.
P2860
Q28817699-AFD7C6C0-C951-4C14-A01F-BC41E4004F75Q34007922-9A564D4C-9693-4B9C-AD52-FF1FC75BD253Q35633324-07581887-88F1-429F-BDEB-F5F75162848DQ35764302-CED2A4C9-127F-4974-9FA6-FC41AAA0C63FQ35803068-62037E80-BED3-4634-9744-97A9086A3219Q37552947-90256B83-3149-4CF8-BFBE-A899B735403CQ38026787-82DB7A2F-9723-4F32-AD59-BC0AB8E46F50Q39378416-36211D37-1758-417D-88E8-C3B33922699CQ39395443-0FE969D6-382A-4932-8F90-FA8D9B77BF0DQ40546253-053462B7-86B6-4F86-898B-A2A9C9D9DB6BQ41913974-A0EE311F-5626-4EC9-A52F-A5769B600492Q41917626-2DA66923-D78D-43FD-B467-953CF4AEB577Q41938203-9FB02B70-0798-4A00-A686-0B9A6936B30CQ41942161-CF60DB9A-7CBA-4D44-92E7-249A7F524D70Q41943280-348901CC-2CC7-4EE4-852E-09DC1C56FC67Q41945144-303A69E7-6866-4D6C-996A-6179F7F24306Q43948799-36BB6DB8-DD0D-4614-902E-1072DB3622CDQ45029023-ECC5897A-B78C-42AB-A41B-9D1F9E3D3D5FQ54660139-FCF71AFF-DECC-487A-84EF-0797CA4CE30A
P2860
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@ast
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@en
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@nl
type
label
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@ast
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@en
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@nl
prefLabel
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@ast
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@en
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@nl
P2093
P2860
P1433
P1476
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
@en
P2093
A Wozniacka
D P McCauliffe
P2860
P356
10.1191/0961203302LU147RR
P577
2002-01-01T00:00:00Z